2IZ · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of 2IZ is 0.1% (very low). The 2025 annual accounts show equity of €207k and a net result of €70k. Equity is growing by ~48.2% per year across the filed fiscal years. Its solvency ranks better than 86% of 2209 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 4 annual accounts.

Signals

3 signals · with evidence

Strong solvency vs sector

Solvency is in the sector's strongest quartile: better than 86% of 2209 peers (2025). A comfortable equity buffer.

View the sector comparison

Consistently profitable

Positive net result in the two most recent financial years (2024 and 2025).

View the result trend

Growing equity

Equity grew over 2023-2025. Profits are largely retained rather than distributed.

View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Filed after the deadline

The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 31-03-2026, 59 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

The next deadline is still running

The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.

How we compute the deadline

The year end is derived from 4 filed financial years, each closing on 30-06. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 30-06-2025, that is 31-01-2026.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
30-06-2025	31-01-2026	31-03-2026	59 d late	2026-00067767
30-06-2024	31-01-2025	26-02-2025	26 d late	2025-00039509
30-06-2023	31-01-2024	28-02-2024	28 d late	2024-00035675
30-06-2022	31-01-2023	28-02-2023	28 d late	2023-00032249

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2021, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

0.1% Very low

0%0,5%1,5%4%10%≥25%

Lower-failure-rate sector −Young company +Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)

EBIT marginNot published (abbreviated filing)

Net result€70k+38.1%

Working capital€185k+52.6%

CSV export

Annual accounts & ratios

Source: NBB · 2025

Annual accounts filed on 31-03-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~48.2%/year over 4 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	89.7%	58.2%	better than 86% of 2209 sector peers
Net result	€70k	€60k	better than 55% of 2207 sector peers
Equity	€207k	€74k	better than 78% of 2209 sector peers
Gross operating margin	€97k	€96k	better than 51% of 2209 sector peers
Total assets	€230k	€187k	better than 59% of 2209 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P86

Improving position over 2022-2025 · n=2209-6573

Net result P55

Stable position over 2022-2025 · n=2207-6567

Equity P78

Improving position over 2022-2025 · n=2209-6573

Gross operating margin P51

Stable position over 2022-2025 · n=2209-6575

Describes the position versus peers, not a forecast.

EBITDA

€96k

+40.5% 22-25

Net profit

€70k

+38.1% 22-25

Cash flow

€74k

+37.0% 22-25

Total assets

€230k

+52.2% 22-25

Equity

€207k

+51.5% 22-25

Working capital

€185k

+52.6% 22-25

Income taxes

€23k

+53.4% 22-25

Debt

€24k

+58.7% 22-25

Debt ≤ 1y

€24k

+58.7% 22-25

Current ratio

8.80

-3.4% 22-25

Quick ratio

8.80

-3.4% 22-25

Solvency

89.7%

-0.5% 22-25

Debt / equity

0.11

+4.7% 22-25

ROE

34.0%

-8.8% 22-25

ROA

30.5%

-9.3% 22-25

Interest coverage

774.44

+35.8% 22-25

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Deposit	micro
Revenue	-
EBITDA	€96k
Net profit	€70k
Cash flow	€74k
Staff costs	-
Income taxes	€23k
Dividends	-
Total assets	€230k
Equity	€207k
Debt	€24k
of which ≤ 1y	€24k
of which > 1y	-
Working capital	€185k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	8.80
Quick ratio	8.80
Working capital ratio	80.1%
Solvency	89.7%
Debt / equity	0.11
Long-term debt ratio	-
Interest coverage	774.44
Gross margin	-
Net margin	-
ROA	30.5%
ROE	34.0%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Assets

Fixed assets €22k · 9.6% Current assets €208k · 90.4%

Equity & liabilities

Equity €207k · 89.7% Debt €24k · 10.3%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€230k
Fixed assets	21/28	€22k
Tangible fixed assets	22/27	€22k
Current assets	29/58	€208k
Amounts receivable within one year	40/41	€9k
Cash & bank	54/58	€136k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€230k
Equity	10/15	€207k
Accumulated profits (losses)	14	€207k
Amounts payable	17/49	€24k
Amounts payable within one year	42/48	€24k
Trade debts payable within one year	44	€959
Income statement
Gross operating margin	9900	€97k
Operating result	9901	€93k
Financial charges	65	€125
Result before taxes	9903	€93k
Income taxes	67/77	€23k
Net result for the period	9904	€70k
Result to be appropriated	9905	€70k

You're seeing the latest fiscal year only. Unlock 3 prior years (figures + ratios) with a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2025 · computed

100 / 100 Excellent

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

from the Crossroads Bank

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Eduard Anseelestraat 672830 Willebroek

Establishment units

1 location

2IZ

Eduard Anseelestraat 67, 2830 WillebroekActiviteiten van tandartspraktijken

since 20212.326.789.973

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels1

Ground area247 m²

Buildings1

Building footprint78 m²

Volume (LiDAR)429 m³

Tallest building9.8 m · ±2 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
12040A0542/00Z010	Flanders	247 m²	1 · 78 m²	9.8 m · 2 fl.

Methodology

via registered seat: 1

1 of 1 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Snowflake analysis

financial profile on 5 axes

94 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 100

Profitability 100

Solvency 100

Growth 78

Stability 94

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers

Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon

The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works